The antimicrobial potential of bacteriophages

Science, Innovation and Technology Committee Closed Inquiry
Opened: 9 Nov 2022 Closed: 28 May 2024 Parliament page
This inquiry is informed by the successful pitch to the Committee’s My Science inquiry. The World Health Organisation has warned that antibiotic resistance (AMR) is one of the biggest threats to global health, food security, and development today, while the Government’s Special Envoy on Antimicrobial Resistance, Dame Sally Davies, has … Read more
23 Recommendations
10 Conclusions
1 Report
3 Oral sessions
3 Events
Activity timeline 8 events
26 Apr
2023
26 Apr
2023
Formal meeting (oral evidence session) · Room 15, Palace of Westminster
15 Mar
2023
15 Mar
2023
Formal meeting (oral evidence session) · Room 6, Palace of Westminster
8 Feb
2023
8 Feb
2023
Formal meeting (oral evidence session) · The Grimond Room, Portcullis House
Oral evidence sessions 3 sessions
Panel One; Panel Two
Dr Jonathan Pearce · Medical Research Council Dr Marc Bailey · Medicines and Healthcare products Regulatory Agency Dr Morwenna Carrington · Department for Health and Social Care Dr Tim Jinks · Wellcome Trust Professor Isabel Oliver · UK Health Security Agency Professor Mark Sutton · UK Centre for Ecology and Hydrology Richard Hebdon · Innovate UK
Dr Hans Petter Kleppen · ACD Pharma Dr Jean-Paul Pirnay · Queen Astrid Military Hospital, Brussels Dr Mzia Kutateladze · George Eliava Institute of Bacteriophage, Microbiology and Virology Greg Merril · Adaptive Phage Therapeutics Naomi Zak · BiomX Professor Jon Iredell · The Westmead Institute for Medical Research Professor Robert Schooley · UC San Diego School of Medicine
Dr James Soothill · Great Ormond Street Hospital Laboratory Medicine Dr Josh Jones · NHS Tayside Mr David Browning · Fixed Phage LTD Ms Stephanie Lesage · Oxford Silk Phage Technologies Ltd Professor Cath Rees · University of Nottingham Professor Joanne M. Santini · University College London Professor Martha Clokie · University of Leicester
Recommendations & Conclusions
1 result
24 Conclusion Accepted in Part
First Report - The antimicrobial p…
Good Manufacturing Practice requirements create impasse for UK phage development
One of the major obstacles to phage clinical trials in the UK has been the requirement for GMP phages. However, regulators require that for phages to achieve GMP standards they must themselves have first been subject to clinical trials. This … Read more
Government Response
The government states that MHRA's draft non-binding advisory guidance will define standards for licensed phages and clarifies that phages for named-patient use require GMP standards but not clinical trials or marketing authorization, thus providing clarity on the described conundrum.
Department for Science, Innovation and Technology
View details
Government Response AI assessment · 33 of 23 classified

Total 23 recs + 10 conclusions